{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:27:24Z","timestamp":1789241244469,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T00:00:00Z","timestamp":1456099200000},"content-version":"vor","delay-in-days":539,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.ihj.2014.08.012","type":"journal-article","created":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T05:41:13Z","timestamp":1412833273000},"page":"530-534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Clopidogrel resistance: The way forward"],"prefix":"10.1016","volume":"66","author":[{"given":"Shuvanan","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2014.08.012_bib1","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2002-10-3027","article-title":"Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270","volume":"101","author":"Ding","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ihj.2014.08.012_bib2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"CAPRIE Streeing Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2014.08.012_bib3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ihj.2014.08.012_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.thromres.2006.08.012","article-title":"Clopidogrel resistance?","volume":"120","author":"Gurbel Paul","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.ihj.2014.08.012_bib5","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2014.08.012_bib6","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ajh.22112","article-title":"Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods","volume":"86","author":"Smock","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ihj.2014.08.012_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1538-7836.2004.01063.x","article-title":"Flow cytometric analysis of intraplatelet VASP phosphorylationfor the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases","volume":"3","author":"Aleil","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ihj.2014.08.012_bib8","doi-asserted-by":"crossref","unstructured":"Gurbel et\u00a0al. Change in inhibition of platelet aggregation (IPA) of <10% using light transmittance aggregometry. Circulation 107:2908\u20132913. http:\/\/dx.doi.org\/10.1161\/01.CIR.0000072771.11429.83.","DOI":"10.1161\/01.CIR.0000072771.11429.83"},{"key":"10.1016\/j.ihj.2014.08.012_bib9","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","article-title":"Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study","volume":"46","author":"Gurbel","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2014.08.012_bib10","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2014.08.012_bib11","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/01.CIR.0000157138.02645.11","article-title":"Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR PLATELETS) study","volume":"111","author":"Gurbel","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2014.08.012_bib12","first-page":"68","article-title":"Dual antiplatelet drug resistance in patients with acute coronary syndrome","volume":"61","author":"Guha","year":"2009","journal-title":"Indian Heart J"},{"key":"10.1016\/j.ihj.2014.08.012_bib13","first-page":"152","article-title":"Profile and prevalence of clopidogrel resistance in patients of acute coronary syndrome","volume":"59","author":"Kumar","year":"2007","journal-title":"Indian Heart J"},{"key":"10.1016\/j.ihj.2014.08.012_bib14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/09537104.2012.693992","article-title":"Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms","volume":"24","author":"Kar","year":"2013","journal-title":"Platelets"},{"key":"10.1016\/j.ihj.2014.08.012_bib15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/01.CIR.0000112378.09325.F9","article-title":"Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance","volume":"109","author":"Lau","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2014.08.012_bib16","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2014.08.012_bib17","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Platelet reactivity & cardiovascular outcomes after percutaneous coronary intervention-a time-dependent ANALYSIS of the Gauging responsiveness with a VerifyNow P2Y12 Assay: impact on thrombosis and safety (GRAVITAS) trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2014.08.012_bib18","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.105.559088","article-title":"Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel. Results of the ISAR-CHOICE (Intracoronary stenting and antithrombotic regimen: choose between 3 high oral doses for immediate clopidogrel effect)","volume":"112","author":"von Beckerath","year":"2005","journal-title":"Trial Circ"},{"key":"10.1016\/j.ihj.2014.08.012_bib19","first-page":"e166","article-title":"ACC\/AHA\/SCAI Writing Committee to update2001 guidelines for percutaneous coronary intervention","volume":"113","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2014.08.012_bib20","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/eurheartj\/ehi877","article-title":"Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease","volume":"27","author":"Winters","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2014.08.012_bib21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcin.2010.12.011","article-title":"Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel the importance of CYP2C19*2 genotyping","volume":"4","author":"Alexopoulos","year":"2011","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.ihj.2014.08.012_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1160\/TH09-07-0482","article-title":"Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study","volume":"103","author":"Montalescot","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ihj.2014.08.012_bib23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2014.08.012_bib24","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","article-title":"Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2014.08.012_bib25","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001948321400265X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001948321400265X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T21:35:33Z","timestamp":1565904933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001948321400265X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S001948321400265X"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2014.08.012","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clopidogrel resistance: The way forward","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2014.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Cardiological Society of India. Published by Elsevier, a division of Reed Elsevier India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}